EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges

Hunter A Holley iD, Maria Lyons, Barry O'Sullivan, Neville Shine, Robbie Woods, Orla McArdle, James Paul O'Neill

Head & Neck · 2025

DOI: 10.1002/hed.70054 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Head & Neck, 2025. Verfasst von Hunter A Holley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Graduate Entry Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy with rising incidence, influenced by ultraviolet (UV) radiation and Merkel cell polyomavirus (MCPyV).

Methods

This review summarizes recent advances in MCC management, based on an analysis of current literature, focusing on immune checkpoint inhibitors (ICIs), viral status implications, and evolving multimodal treatment strategies.

Results

MCPyV‐positive MCC has a median overall survival (OS) of 6.6 years compared to 1.2 years for virus‐negative cases. The 5‐year OS rate for localized MCC is approximately 50%. Historically, the 5‐year OS for metastatic MCC was ~14%, but has significantly improved with ICIs. First‐line treatment with avelumab achieved a median OS of 20.3 months and a 5‐year OS of approximately 26%. Pembrolizumab demonstrated a median OS of 24.3 months, a median progression‐free survival (PFS) of 9.3 months, and a durable response with a median duration of response (DOR) of 39.8 months.

Conclusion

Despite advances, MCC recurrence rates remain high (16.4% local, 32.1% regional, 9.5% distant), necessitating vigilant long‐term surveillance. Future research should focus on optimizing combination therapies, identifying predictive biomarkers, and refining treatment sequencing to further improve survival and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSkin NeoplasmsImmune Checkpoint InhibitorsHumansAntibodies, Monoclonal, HumanizedCombined Modality TherapyMerkel cell polyomavirus

Stichwörter der Autor:innen

Merkel Cell Carcinomaimmunotherapypathogenesisprognosistherapeutics

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedavelumabpembrolizumab

Autor:innen und Institutionen

  • Department of Graduate Entry Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland.
  • Department of Otolaryngology Head and Neck Surgery, RCSI, Dublin, Ireland.
  • Department of Plastic Surgery, Beaumont Hospital, Dublin, Ireland.
  • St. Luke's Radiation Oncology Network, Dublin, Ireland.
  • Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.

ORCID-Profile: Hunter A Holley

Zitieren

APA

Holley, H. A., Lyons, M., O'Sullivan, B., Shine, N., Woods, R., McArdle, O., & O'Neill, J. P. (2025). Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges. Head & Neck. https://doi.org/10.1002/hed.70054

Vancouver

Holley HA, Lyons M, O'Sullivan B, Shine N, Woods R, McArdle O, et al. Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges. Head & Neck. 2025. doi:10.1002/hed.70054

BibTeX
@article{Holley2025,
  author = {Holley, Hunter A and Lyons, Maria and O'Sullivan, Barry and Shine, Neville and Woods, Robbie and McArdle, Orla and O'Neill, James Paul},
  title = {Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.70054}
}
Kostenlos starten →